Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kanamycin + metronidazole is a synergistic antibiotic combination that demonstrates enhanced efficacy against various bacterial infections. Kanamycin is an aminoglycoside that prevents bacterial protein synthesis by binding to 16S rRNA of the 30S ribosomal subunit, while metronidazole is reduced to cytotoxic compounds that cause DNA damage in bacteria. When combined, these antibiotics show significant synergy with drastically reduced minimum inhibitory concentrations, allowing for lower doses while maintaining or enhancing antimicrobial activity. This combination is effective against a wide spectrum of pathogens including gram-positive and gram-negative bacteria, anaerobic bacteria, and certain protozoa.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kanamycin + metronidazole.